OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-based combined therapies. We performed network meta-analysis (NMA) to compare the outcomes, including progression-free survival (PFS) and objective response rates (ORRs), in patients with intermediate- and poor-risk mRCC; we also assessed treatment-related adverse events. RESULTS: Overall, seven RCTs were included in the meta-analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72-1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. CONCLUSIONS: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first-line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.

Cancer Prognostics and Health Outcomes Unit Division of Urology University of Montreal Health Center Montreal Québec Canada

Clinic of Urology and Urological Oncology Jagiellonian University Krakow Poland

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia

Department of Urology La Croix Du Sud Hospital Quint Fonsegrives France

Department of Urology Medical University of Silesia Zabrze Poland

Department of Urology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Urology Department of Special Surgery The University of Jordan Amman Jordan

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Zobrazit více v PubMed

Ljungberg B, Albiges L, Abu‐Ghanem Y et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 2022; 82: 399–410

Motzer RJ, Jonasch E, Agarwal N et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022; 20: 71–90

Lombardi P, Filetti M, Falcone R et al. New first‐line immunotherapy‐based combinations for metastatic renal cell carcinoma: a systematic review and network meta‐analysis. Cancer Treat Rev 2022; 106: 102377

Mori K, Mostafaei H, Miura N et al. Systemic therapy for metastatic renal cell carcinoma in the first‐line setting: a systematic review and network meta‐analysis. Cancer Immunol Immunother 2021; 70: 265–273

Quhal F, Mori K, Bruchbacher A et al. First‐line immunotherapy‐based combinations for metastatic renal cell carcinoma: a systematic review and network meta‐analysis. Eur Urol Oncol 2021; 4: 755–765

Choueiri TK, Powles TB, Albiges L et al. LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC‐313). Ann Oncol 2022; 33: S1430–S1431

Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100

Motzer R, Alekseev B, Rha SY et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021; 384: 1289–1300

Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928

Connor MJ, Shah TT, Smigielska K et al. Additional treatments to the local tumour for metastatic prostate cancer‐Assessment of Novel Treatment Algorithms (IP2‐ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open 2021; 11: e042953

van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta‐analysis. Res Synth Methods 2012; 3: 285–299

Woods BS, Hawkins N, Scott DA. Network meta‐analysis on the log‐hazard scale, combining count and hazard ratio statistics accounting for multi‐arm trials: a tutorial. BMC Med Res Methodol 2010; 10: 54

Choueiri TK, Motzer RJ, Rini BI et al. Updated efficacy results from the JAVELIN Renal 101 trial: first‐line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020; 31: 1030–1039

Grünwald V, Powles T, Kopyltsov E et al. Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. J Clin Oncol 2021; 39: 4560

Motzer RJ, Penkov K, Haanen J et al. Avelumab plus axitinib versus sunitinib for advanced renal‐cell carcinoma. N Engl J Med 2019; 380: 1103–1115

Motzer RJ, Powles T, Burotto M et al. Nivolumab plus cabozantinib versus sunitinib in first‐line treatment for advanced renal cell carcinoma (CheckMate 9ER): long‐term follow‐up results from an open‐label, randomised, phase 3 trial. Lancet Oncol 2022; 23: 888–898

Motzer RJ, Rini BI, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in first‐line treatment for advanced renal cell carcinoma: extended follow‐up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20: 1370–1385

Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal‐cell carcinoma. N Engl J Med 2018; 378: 1277–1290

Powles T, Plimack ER, Soulières D et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first‐line treatment of advanced renal cell carcinoma (KEYNOTE‐426): extended follow‐up from a randomised, open‐label, phase 3 trial. Lancet Oncol 2020; 21: 1563–1573

Rini BI, Plimack ER, Stus V et al. Pembrolizumab plus Axitinib versus sunitinib for advanced renal‐cell carcinoma. N Engl J Med 2019 Mar; 21: 1116–1127

Shea BJ, Reeves BC, Wells G et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non‐randomised studies of healthcare interventions, or both. BMJ 2017; 358: j4008

Hammers HJ, Plimack ER, Infante JR et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study. J Clin Oncol 2017; 35: 3851–3858

Wolchok JD, Saenger Y. The mechanism of anti‐CTLA‐4 activity and the negative regulation of T‐cell activation. Oncologist 2008; 13(Suppl 4): 2–9

Hellmann MD, Paz‐Ares L, Bernabe Caro R et al. Nivolumab plus ipilimumab in advanced non‐small‐cell lung cancer. N Engl J Med 2019; 381: 2020–2031

Wolchok JD, Chiarion‐Sileni V, Gonzalez R et al. Long‐term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022; 40: 127–137

Apolo AB, Powles T, Escudier B et al. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: results from a discontinued arm of the phase III CheckMate 9ER trial. Eur J Cancer 2022; 177: 63–71

Albiges L, Tannir NM, Burotto M et al. Nivolumab plus ipilimumab versus sunitinib for first‐line treatment of advanced renal cell carcinoma: extended 4‐year follow‐up of the phase III CheckMate 214 trial. ESMO Open 2020; 5: e001079

Mori K, Quhal F, Yanagisawa T et al. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta‐analysis. Int Immunopharmacol 2022; 108: 108720

Méjean A, Ravaud A, Thezenas S et al. Sunitinib alone or after nephrectomy in metastatic renal‐cell carcinoma. N Engl J Med 2018; 379: 417–427

Chakiryan NH, Gore LR, Reich RR et al. Survival outcomes associated with cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma. JAMA Netw Open 2022; 5: e2212347

Singla N, Hutchinson RC, Ghandour RA et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol 2020; 38: 604.e9–604.e17